← Back to Search

Epinephrine Alternative

1 mg/100 µL dose of ARS-1 for Asthma

Phase 2
Waitlist Available
Research Sponsored by ARS Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (timepoints 0) to 1 hour
Awards & highlights

Study Summary

This trial is testing a needle-free way to give epinephrine to people with severe asthma who aren't helped by other treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (timepoints 0) to 1 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (timepoints 0) to 1 hour for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effect of ARS-1 versus Albuterol and placebo

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: 1 mg/100 µL dose of ARS-1Active Control1 Intervention
Group II: 2 mg/100 µL dose of ARS-1Active Control1 Intervention
Group III: albuterol MDI (180 mcg)Active Control1 Intervention
Group IV: placeboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

ARS Pharmaceuticals, Inc.Lead Sponsor
2 Previous Clinical Trials
47 Total Patients Enrolled
Sarina Tanimoto, MD, PhDStudy DirectorARS Pharmaceuticals, Inc.
1 Previous Clinical Trials
32 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~11 spots leftby May 2025